Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.

2.

AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence

3.

Efanesoctocog Alfa Prevented Bleeding in Kids With Severe Hemophilia A

4.

For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.

5.

Win for Perioperative Durvalumab in Muscle-Invasive Bladder Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot